Back to Archived Journals » Research and Reports in Biochemistry » Volume 5

Targeting the endoplasmic reticulum in prion disease treatment: breakthroughs and challenges

Authors Kanemoto S

Received 15 September 2014

Accepted for publication 28 November 2014

Published 23 January 2015 Volume 2015:5 Pages 31—38


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Nikolay Dokholyan

Soshi Kanemoto

Department of Biochemistry, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan

Abstract: Prion diseases are infectious, predominantly fatal neurodegenerative diseases characterized by abnormal prion protein (PrP) accumulation and neuronal loss. Studies on experimental animal models and clinical features of human prion diseases have shown unfolded PrP accumulation results in endoplasmic reticulum (ER) stress. While ER stress-mediated apoptosis is responsible for neuronal loss in prion diseases, ER stress also activates the unfolded protein response (UPR) in an effort to restore ER homeostasis. Of the UPR signaling pathways, the PERK-eIF2α pathway is implicated in the pathogenesis of prion diseases. The proteasome protein degradation system is also activated during the UPR. Increasing evidence indicates that proteasome and autophagy activities are affected in prion diseases. These findings suggest that ER stress/UPR contributes to the onset of prion diseases. Hence, strategies that target the ER are useful approaches in treating prion diseases. Additionally, immunotherapeutic approaches for prion diseases have been developed in recent decades. Single-chain fragment variable antibodies targeting the accumulation of PrP are also beneficial in the prevention of abnormal PrP propagation. This review discusses pathogenic mechanisms related to the ER and potential strategies for treating prion diseases.

Keywords: prion, endoplasmic reticulum, unfolded protein response, therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]